Oncopeptides AB Registered Shs Aktie [WKN DE: A2DLU2 / ISIN: SE0009414576]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Oncopeptides AB Registered Shs

15.06.20		Oncopeptides Reports Positive Results From Full Data Set of Phase 2 HORIZON Trial in Triple-class Refractory Multiple Myeloma Patients (PR Newswire)
11.06.20		Oncopeptides Hosts a Virtual Symposium at the 25th European Hematology Association Congress on Challenges in Managing Patients with Myeloma (PR Newswire)
11.06.20		Oncopeptides Hosts a Virtual Symposium at the 25th European Hematology Association Congress on Challenges in Managing Patients with Myeloma (PR Newswire)
01.06.20		New Analysis Confirms That Multiple Myeloma Patients in the OCEAN Study Stay on Treatment Longer Than Previously Estimated - Results Expected H1-2021 (PR Newswire)
01.06.20		New Analysis Confirms That Multiple Myeloma Patients in the OCEAN Study Stay on Treatment Longer Than Previously Estimated - Results Expected H1-2021 (PR Newswire)
29.05.20		Number of shares and votes in Oncopeptides (PR Newswire)
29.05.20		Number of shares and votes in Oncopeptides (PR Newswire)
28.05.20		Oncopeptides Reinitiates Patient Enrollment to the Melflufen Clinical Program Following a Temporary Pause due to the COVID-19 Pandemic (PR Newswire)
28.05.20		Oncopeptides Reinitiates Patient Enrollment to the Melflufen Clinical Program Following a Temporary Pause due to the COVID-19 Pandemic (PR Newswire)
26.05.20		Bulletin From the Annual General Meeting in Oncopeptides AB (publ) (PR Newswire)
26.05.20		Bulletin From the Annual General Meeting in Oncopeptides AB (publ) (PR Newswire)
26.05.20		Oncopeptides AB: Interim Report Q1 2020 (PR Newswire)
26.05.20		Oncopeptides AB: Interim Report Q1 2020 (PR Newswire)
22.05.20		Oncopeptides Completes Enrollment to the Pivotal Phase 3 Study OCEAN for Relapsed Refractory Multiple Myeloma - 450 Patients Included (PR Newswire)
22.05.20		Oncopeptides Completes Enrollment to the Pivotal Phase 3 Study OCEAN for Relapsed Refractory Multiple Myeloma - 450 Patients Included (PR Newswire)
15.05.20		Oncopeptides Presents Pre-clinical Melflufen Data at the AACR Annual Meeting 2020 That Further Validates the Technical Platform, PDC (PR Newswire)
15.05.20		Oncopeptides Presents Pre-clinical Melflufen Data at the AACR Annual Meeting 2020 That Further Validates the Technical Platform, PDC (PR Newswire)
14.05.20		Oncopeptides Announces New Clinical and Preclinical Melflufen Data at the Upcoming European Hematology Association Meeting (PR Newswire)
14.05.20		Oncopeptides Announces New Clinical and Preclinical Melflufen Data at the Upcoming European Hematology Association Meeting (PR Newswire)
13.05.20		Oncopeptides Announces that Two Abstracts on Multiple Myeloma have been Accepted by the 2020 ASCO Annual Meeting (PR Newswire)
13.05.20		Oncopeptides Announces that Two Abstracts on Multiple Myeloma have been Accepted by the 2020 ASCO Annual Meeting (PR Newswire)
28.04.20		Oncopeptides Annual Report 2019 (PR Newswire)
28.04.20		Oncopeptides Annual Report 2019 (PR Newswire)
22.04.20		Annual General Meeting in Oncopeptides AB (publ) (PR Newswire)
22.04.20		Annual General Meeting in Oncopeptides AB (publ) (PR Newswire)
02.04.20		Oncopeptides Strengthens its Corporate Communications Function by Appointing Rolf Gulliksen as Global Head of Corporate Communications (PR Newswire)
02.04.20		Oncopeptides Strengthens its Corporate Communications Function by Appointing Rolf Gulliksen as Global Head of Corporate Communications (PR Newswire)
26.03.20		Oncopeptides Announces 26% Overall Response Rate of Melflufen in Triple-class Refractory Multiple Myeloma Patients From the Pivotal HORIZON Study (PR Newswire)
26.03.20		Oncopeptides Announces 26% Overall Response Rate of Melflufen in Triple-class Refractory Multiple Myeloma Patients From the Pivotal HORIZON Study (PR Newswire)
24.03.20		The Lancet Haematology Publishes Results From Oncopeptides' Multicenter, International Phase 1/2 Study (O-12-M1) (PR Newswire)
24.03.20		The Lancet Haematology Publishes Results From Oncopeptides' Multicenter, International Phase 1/2 Study (O-12-M1) (PR Newswire)
20.03.20		Oncopeptides Provides Update Regarding COVID-19 Impact on the Melflufen Clinical Program (PR Newswire)
20.03.20		Oncopeptides Provides Update Regarding COVID-19 Impact on the Melflufen Clinical Program (PR Newswire)
02.03.20		Oncopeptides Strengthens its Organization by Appointing Karolina Vilval as General Counsel (PR Newswire)
02.03.20		Oncopeptides Strengthens its Organization by Appointing Karolina Vilval as General Counsel (PR Newswire)
24.01.20		Oncopeptides will Host a Webcast on Monday, January 27th at 11.00 (CET) (PR Newswire)
24.01.20		Oncopeptides will Host a Webcast on Monday, January 27th at 11.00 (CET) (PR Newswire)
07.01.20		Oncopeptides Strengthens its Regulatory Function by Appointing Karin Eklund Vanderpol as Head of Regulatory Affairs (PR Newswire)
07.01.20		Oncopeptides Strengthens its Regulatory Function by Appointing Karin Eklund Vanderpol as Head of Regulatory Affairs (PR Newswire)
17.12.19		Bulletin From the Extraordinary General Meeting in Oncopeptides AB (publ) (PR Newswire)
17.12.19		Bulletin From the Extraordinary General Meeting in Oncopeptides AB (publ) (PR Newswire)
08.12.19		Oncopeptides Presents Promising Data from the Phase 2 ANCHOR Combination Study in Patients With RRMM at ASH Annual Meeting 2019 (PR Newswire)
08.12.19		Oncopeptides Presents Promising Data from the Phase 2 ANCHOR Combination Study in Patients With RRMM at ASH Annual Meeting 2019 (PR Newswire)
07.12.19		Oncopeptides Presents Updated Efficacy and Safety Data from Pivotal Phase 2 HORIZON Study in Patients With RRMM at ASH Annual Meeting 2019 (PR Newswire)
07.12.19		Oncopeptides Presents Updated Efficacy and Safety Data from Pivotal Phase 2 HORIZON Study in Patients With RRMM at ASH Annual Meeting 2019 (PR Newswire)
06.12.19		Oncopeptides Will Host a Webcast on Tuesday, December 10th at 13:00 (CET) to Provide an Update Regarding Data Presented at the ASH Annual Meeting (PR Newswire)
06.12.19		Oncopeptides Will Host a Webcast on Tuesday, December 10th at 13:00 (CET) to Provide an Update Regarding Data Presented at the ASH Annual Meeting (PR Newswire)
02.12.19		Oncopeptides Appoints Joseph Horvat as President North America (PR Newswire)
02.12.19		Oncopeptides Appoints Joseph Horvat as President North America (PR Newswire)
14.11.19		Extraordinary General Meeting in Oncopeptides AB (publ) (PR Newswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Meistgelesene Nachrichten

Solana Kurs Prognose: – 10 Prozent in einer Woche – Jetzt schnell verkaufen?

EU-Abgeordnete fordert Bitcoin statt digitalem Euro - strategische Bitcoin-Reserve für die EU

Diese Aktien empfehlen Experten zu kaufen

APA - N A C H R I C H T E N Ü B E R B L I C K

Fed-Gouverneurin Lisa Cook und Experten sprechen klare Warnung über mögliche Korrekturen 2025 aus

Steinmeier setzt Neuwahlen für 23. Februar an

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	13.01.2025 18:06
Kaufwert:	EUR
	Hinzufügen Speichern